HPS Pharmacies wishes to advise that Novo Nordisk is discontinuing Saxenda® as follows:

Saxenda®
Liraglutide (rys) 6mg/mL
ARTG 225804

Saxenda® will be discontinued on 19th December 2025. Patients currently receiving Saxenda® should discuss alternative treatment options with their prescriber.

Other injectable medications indicated for weight management include:

  • Semaglutide (Wegovy®) – an alternative glucagon-like peptide-1 (GLP-1) analogue; and
  • Tirzepatide (Mounjaro®) – a dual agonist at GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates